SLIDE 1.png (126.57 kB)

How to Optimise Extended Adjuvant Treatment with Neratinib for Patients with Early HER2+ Breast Cancer

media

posted on 2021-05-20, 16:13 authored by Adis Rapid Journals on behalf of:, Michael Untch, Miguel Martin, Michelino De Laurentiis, Joseph Gligorov

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

Usage metrics

Keywords

Adjuvant treatment early breast cancer efficacy extended treatment human epidermal growth factor receptor 2-positive hormone receptor-positive neratinib tolerability trastuzumab tyrosine kinase inhibitor

Licence

CC BY-NC 4.0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM